{"id":35811,"date":"2025-06-19T12:00:00","date_gmt":"2025-06-19T10:00:00","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/06\/19\/bk-virus-specific-t-cell-response-associated-with-hla-genotypes-rhd-status-and-cmv-or-ebv-serostatus-in-healthy-donors-for-optimized-cell-therapy\/"},"modified":"2025-06-19T12:00:00","modified_gmt":"2025-06-19T10:00:00","slug":"bk-virus-specific-t-cell-response-associated-with-hla-genotypes-rhd-status-and-cmv-or-ebv-serostatus-in-healthy-donors-for-optimized-cell-therapy","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/06\/19\/bk-virus-specific-t-cell-response-associated-with-hla-genotypes-rhd-status-and-cmv-or-ebv-serostatus-in-healthy-donors-for-optimized-cell-therapy\/","title":{"rendered":"BK Virus-Specific T Cell Response Associated with HLA Genotypes, RhD Status, and CMV or EBV Serostatus in Healthy Donors for Optimized Cell Therapy"},"content":{"rendered":"<div>\n<p><b>J Clin Immunol<\/b>. 2025 Jun 19;45(1):109. doi: 10.1007\/s10875-025-01901-2.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>PURPOSE: The increasing application of virus-specific T cell therapy for treating BK virus infections in immunocompromised patients highlights the necessity for rapid identification of compatible cell donors with optimal BK-specific T cell response. This study aims to characterize the BK virus-specific T cell response in relation to demographic factors, blood group, serological status, and HLA genotypes using samples from a cell donor registry.<\/p>\n<p>METHODS: Peripheral blood mononuclear cells from cell donors were stimulated with peptide pools derived from VP1 and LTA proteins, and the IFN-\u03b3 production was analyzed using ELISpot and validated by flow cytometry.<\/p>\n<p>RESULTS: Our findings provide an overview of the T cell response to BK virus proteins in healthy donors, revealing associations with demographic characteristics, RhD status, CMV or EBV serological status, and HLA alleles. Remarkably, RhD-negative, CMV-seronegative, and EBV-seronegative donors showed a major T cell response against BK virus proteins. Notably, certain HLA alleles were associated with either enhanced or diminished T cell response. Furthermore, our results suggest that HLA-B leader dimorphism, specifically the presence of threonine at position 2, influences the VP1-specific immune response, resulting in enhanced T cell activation.<\/p>\n<p>CONCLUSION: This study, beyond advancing our understanding of the relationship between donor characteristics and BK virus-specific T cell response, has significant implications for improving the selection of optimal cell donors for patient-specific adoptive therapy.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40537681\/?utm_source=WordPress&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=8102137&amp;ff=20250620004712&amp;v=2.18.0.post9+e462414\">40537681<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1007\/s10875-025-01901-2\">10.1007\/s10875-025-01901-2<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Clin Immunol. 2025 Jun 19;45(1):109. doi: 10.1007\/s10875-025-01901-2. ABSTRACT PURPOSE: The increasing application of virus-specific T cell therapy for treating BK virus infections in immunocompromised patients highlights the necessity for rapid identification of compatible cell donors with optimal BK-specific T cell response. This study aims to characterize the BK virus-specific T cell response in relation &#8230; <a title=\"BK Virus-Specific T Cell Response Associated with HLA Genotypes, RhD Status, and CMV or EBV Serostatus in Healthy Donors for Optimized Cell Therapy\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/06\/19\/bk-virus-specific-t-cell-response-associated-with-hla-genotypes-rhd-status-and-cmv-or-ebv-serostatus-in-healthy-donors-for-optimized-cell-therapy\/\" aria-label=\"Read more about BK Virus-Specific T Cell Response Associated with HLA Genotypes, RhD Status, and CMV or EBV Serostatus in Healthy Donors for Optimized Cell Therapy\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[69,42],"tags":[],"class_list":["post-35811","post","type-post","status-publish","format-standard","hentry","category-journal-of-clinical-immunology","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/35811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=35811"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/35811\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=35811"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=35811"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=35811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}